Core Insights - Nurix Therapeutics has announced that Sanofi has exercised its option to exclusively license Nurix's STAT6 program, which includes the drug candidate NX-3911, a selective STAT6 degrader [2][3] - The collaboration agreement from 2019 has resulted in a total of $127 million received by Nurix, with the potential for an additional $465 million in development, regulatory, and commercial milestones [1][3] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for patients with cancer and inflammatory diseases [5][6] - The company utilizes its proprietary DEL-AI drug discovery platform to identify novel agents that induce degradation of specified drug targets, with a focus on E3 ligases [3][6] Product Development - NX-3911 is a potent, orally administered STAT6 degrader that has shown robust efficacy in preclinical models for atopic dermatitis and asthma, demonstrating anti-inflammatory effects comparable to a STAT6 gene knockout [3][4] - The STAT6 program also includes additional differentiated discovery-stage assets, representing further product opportunities within the collaboration with Sanofi [3] Financial Aspects - Under the collaboration agreement, Sanofi made an upfront payment of $55 million and an additional $22 million to expand the collaboration scope, with Nurix eligible for royalties on future sales [3] - Nurix retains the option to co-develop and co-promote up to two future products in the U.S., sharing profits and losses evenly with Sanofi [3]